The receptor agonists of GLP-1 (GLP-1 RAs) are able to increase the hyperglycemia-induced insulin secretion and decrease glucagon secretion, delay gastric emptying, reduce appetite and caloric intake, and they are strongly recommended in T2DM treatment [13]. The gene discussed is INS; the disease is type 2 diabetes mellitus.